Payment processing for prescription telehealth peptide clinics.
Direct merchant accounts for licensed telehealth practices and compounding-pharmacy partners fulfilling human-clinical peptide prescriptions.
Prescription peptide telehealth (BPC-157, thymosin, semaglutide protocols, HRT-adjacent peptides) sits in the same underwriting lane as GLP-1 telehealth and compounded-pharmacy fulfillment. Acquirers that openly serve the vertical want a prescription-required model, licensed telehealth workflow, 503A/503B compounding-pharmacy fulfillment on file, and clear marketing that does not lean into off-label or performance claims. We place these files at banks that already board the category, package the compliance documentation the risk desk expects, and tune the chargeback workflow for subscription telehealth billing.
Prescription peptide telehealth is legal when structured correctly: licensed prescriber, patient intake protocol, 503A or 503B compounding pharmacy fulfillment, and marketing that does not lean into off-label or performance claims. Your product pages, disclaimers, and refund policy have to reflect that model. We help package the compliance posture before underwriting sees the file.
We place you with banks that openly serve the vertical, so your account won't be terminated for selling peptides per se. Termination still happens for the same reasons it does in any vertical: chargeback ratio above 1%, fraud, or a material change to your business that wasn't disclosed.
Yes. Subscription is the dominant pattern in the category. Tokenized recurring with smart retry on declines, customer-facing self-serve cancellation, and dunning workflows are all built in. The trick is keeping the dispute ratio low, which is why our representment is built specifically for this category.